1
|
Gao X, Huang M, Liu L, et al:
Insertion/deletion polymorphisms in the promoter region of BRM
contribute to risk of hepatocellular carcinoma in Chinese
populations. PLoS One. 8:e551692013.
|
2
|
Ying H, Wang J and Gao X: CCL5-403,
CCR5-59029, and Delta32 polymorphisms and cancer risk: a
meta-analysis based on 20,625 subjects. Tumour Biol. 35:5895–5904.
2014.
|
3
|
Schneeberger A, Koszik F and Stingl G:
Immunologic host defense in melanoma: delineation of effector
mechanisms involved and of strategies for the augmentation of their
efficacy. J Invest Dermatol. 105(Suppl 1): S110–S116. 1995.
|
4
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003.
|
5
|
Roncador G, Garcia JF, Garcia JF, et al:
FOXP3, a selective marker for a subset of adult T-cell
leukemia/lymphoma. Leukemia. 19:2247–2253. 2005.
|
6
|
Wang L, Liu R, Li W, et al: Somatic single
hits inactivate the X-linked tumor suppressor FOXP3 in the
prostate. Cancer Cell. 16:336–346. 2009.
|
7
|
Zuo T, Liu R, Zhang H, et al: FOXP3 is a
novel transcriptional repressor for the breast cancer oncogene
SKP2. J Clin Invest. 117:3765–3773. 2007.
|
8
|
Bennett CL, Brunkow ME, Ramsdell F, et al:
A rare polyadenylation signal mutation of the FOXP3 gene
(AAUAAA→AAUGAA) leads to the IPEX syndrome. Immunogenetics.
53:435–439. 2001.
|
9
|
Gupta S, Joshi K, Wig JD and Arora SK:
Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its
association with clinicopathologic parameters and angiogenesis.
Acta Oncol. 46:792–797. 2007.
|
10
|
Karanikas V, Speletas M, Zamanakou M, et
al: FOXP3 expression in human cancer cells. J Transl Med.
6:192008.
|
11
|
Katoh H, Zheng P and Liu Y: Signalling
through FoxP3 as an X-linked tumor suppressor. Int J Biochem Cell
Biol. 42:1784–1787. 2010.
|
12
|
Chen Y, Zhang H, Liao W, et al: FOXP3 gene
polymorphism is associated with hepatitis B-related hepatocellular
carcinoma in China. J Exp Clin Cancer Res. 32:392013.
|
13
|
He YQ, Bo Q, Yong W, Qiu ZX, Li YL and Li
WM: FoxP3 genetic variants and risk of non-small cell lung cancer
in the Chinese Han population. Gene. 531:422–425. 2013.
|
14
|
Jahan P, Ramachander VR, Maruthi G, Nalini
S, Latha KP and Murthy TS: Foxp3 promoter polymorphism (rs3761548)
in breast cancer progression: a study from India. Tumour Biol.
35:3785–3791. 2014.
|
15
|
Raskin L, Rennert G and Gruber SB: FOXP3
germline polymorphisms are not associated with risk of breast
cancer. Cancer Genet Cytogenet. 190:40–42. 2009.
|
16
|
Zheng J, Deng J, Jiang L, et al:
Heterozygous genetic variations of FOXP3 in Xp11.23 elevate breast
cancer risk in Chinese population via skewed X-chromosome
inactivation. Hum Mutat. 34:619–628. 2013.
|
17
|
Higgins JP and Thompson SG: Quantifying
heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002.
|
18
|
Mantel N and Haenszel W: Statistical
aspects of the analysis of data from retrospective studies of
disease. J Natl Cancer Inst. 22:719–748. 1959.
|
19
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
|
20
|
Zuo T, Wang L, Morrison C, et al: FOXP3 is
an X-linked breast cancer suppressor gene and an important
repressor of the HER-2/ErbB2 oncogene. Cell. 129:1275–1286.
2007.
|
21
|
Liu R, Wang L, Chen G, et al: FOXP3
up-regulates p21 expression by site-specific inhibition of histone
deacetylase 2/histone deacetylase 4 association to the locus.
Cancer Res. 69:2252–2259. 2009.
|
22
|
Li W, Wang L, Katoh H, et al:
Identification of a tumor suppressor relay between the FOXP3 and
the Hippo pathways in breast and prostate cancers. Cancer Res.
71:2162–2171. 2011.
|
23
|
Katoh H, Qin ZS, Liu R, et al: FOXP3
orchestrates H4K16 acetylation and H3K4 trimethylation for
activation of multiple genes by recruiting MOF and causing
displacement of PLU-1. Mol Cell. 44:770–784. 2011.
|
24
|
Marson A, Kretschmer K, Frampton GM, et
al: FoxP3 occupancy and regulation of key target genes during
T-cell stimulation. Nature. 445:931–935. 2007.
|